imm8k-082907.htm
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported)
August
24, 2007
IMMTECH
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
(State
or Other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
One
North End Avenue
New
York, New York 10282
(Address
of Principal Executive Offices, including Zip Code)
(212)
791-2911
(Registrant’s
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM 5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment
of
Certain Officers; Compensatory Arrangements of Certain
Officers.
|
(d)
Election of New Directors
Effective
August 24, 2007, the Board of Directors of Immtech Pharmaceuticals, Inc. (the
“Company”) appointed David Martin Fleet a director of the
Company. Mr. Fleet’s term will expire at the Company’s next Annual
Meeting of Stockholders.
Mr.
Fleet
has served as principal of David Fleet Pharmaceutical Industry Consultancy
Services since 2003, and has been the non-executive director of OnMedica Group
Ltd. since 2004. He also has served as a senior vice president of
global business development of Innovex Ltd. – Quintiles Transnational from 2000
to 2002. Mr. Fleet has over 35 years of experience in the
international pharmaceutical industry including experience in business
development, sales and marketing, manufacturing and technical roles in the
U.S.,
Japan, Europe, and the Middle East. Mr.
Fleet
is a member of the Royal Pharmaceutical Society of Great Britain, and was
educated at the School of Pharmacy at the University of
Liverpool.
Board
committee assignments have not yet been determined for Mr.
Fleet. There are no transactions in which Mr. Fleet has an interest
requiring disclosure under Item 404(a) of Regulation S-K. As a
non-employee director, Mr. Fleet will receive compensation in accordance with
the Company’s policies for compensating outside directors including options to
purchase 20,000 shares of the Company’s common stock upon joining the Board of
Directors, and annual compensation of $20,000 and options to purchase 15,000
shares of the Company’s common stock for each year served on the Board
Directors. All such options vest in twenty-four equal monthly
installments from the date of grant.
The
Company issued a press release announcing the appointment of Mr. Fleet to the
Company’s Board, which is attached hereto as Exhibit 99.1 and incorporated
herein by reference. The press release is being furnished to the SEC
and shall not be deemed to be “filed” for any purpose.
ITEM 9.01
|
Financial
Statements and Exhibits.
|
|
99.1
|
Press
Release, dated August 28, 2007, of Immtech Pharmaceuticals, Inc.
regarding
the appointment of David Martin Fleet to the Board of
Directors.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
August 28, 2007
|
Immtech
Pharmaceuticals, Inc.
|
|
|
|
|
|
Eric
L. Sorkin
Chairman,
Chief Executive Officer and
President
|
Exhibit
Index
Exhibit
No.
|
Description
|
|
|
EX-99.1
|
Press
Release, dated August 28, 2007, of Immtech Pharmaceuticals, Inc.
regarding
the appointment of David Martin Fleet to the Board of
Directors.
|